ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis

    Maurits C.F.J. De Rotte1, Ethan den Boer2, Maja Bulatovic3, Saskia M.F. Pluijm4, Johanna M.W. Hazes5 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Public Health, Erasmus Medical center, Rotterdam, Netherlands, 5Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
  • Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting

    The Changed Prognosis of Patients with Early Rheumatoid Arthritis

    Karin Britsemmer1 and Dirkjan van Schaardenburg2, 1Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
  • Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting

    Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?

    C.J. Inman1, Frederick Wolfe2 and Kaleb Michaud3, 1Pediatric Administration, University of Utah, Salt Lake City, UT, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
  • Abstract Number: 1587 • 2012 ACR/ARHP Annual Meeting

    Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally

    Malin Regardt1, Marie-Louise Schult2, Ingrid E. Lundberg3 and Elisabet MB Welin Henriksson4, 1Department of Occupational Therapy, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, 3Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4Medicine, Karolinska Institutet Rheum, Stockholm, Sweden

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness. A recent study has shown that patients with PM and DM have reduced…
  • Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting

    Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis

    Kevin L. Winthrop1, S.-H. Park2, A. Gul3, M. Cardiel4, JJ Gomez-Reino5, D. Ponce de Leon6, R. Riese7, R. Chew7, T. Kawabata7, E. Mortensen6 and H. Valdez8, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2The Catholic University of Korea, Seoul, South Korea, 3Istanbul University, Istanbul, Turkey, 4Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, 5Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 6Pfizer Inc., Collegeville, PA, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., New York, NY

    Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
  • Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months

    Jurgen Wollenhaupt1, Joel C. Silverfield2, Eun Bong Lee3, Susan P. Wood4, Koshika Soma5, Lisy Wang4, Hiroyuki Nakamura6, Yoshihiro Komuro6, Chudi I. Nduaka4, David Gruben4, Birgitta Benda7, Samuel H. Zwillich5, Richard Riese4 and John D. Bradley4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc., Groton, CT, 5Pfizer Inc, Groton, CT, 6Pfizer Japan Inc., Tokyo, Japan, 7Pfizer Inc., Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
  • Abstract Number: 1125 • 2012 ACR/ARHP Annual Meeting

    Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study

    Jasmijn F. M. Holla1, Marike van der Leeden1, Leo D. Roorda2, Martijn W. Heymans3, Sita M.A. Bierma-Zeinstra4, Maarten Boers5, Willem F. Lems6, Martijn P.M. Steultjens7 and Joost Dekker8, 1Amsterdam Rehabilitation Research Center, Reade, Amsterdam, Netherlands, 2Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 3Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 4Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 5Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 6Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 7Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, 8Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Knee osteoarthritis (OA) is one of the leading causes of activity limitations among older adults. The course of activity limitations is highly variable; some…
  • Abstract Number: 1126 • 2012 ACR/ARHP Annual Meeting

    Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up

    Janet Wesseling1, Sita M.A. Bierma-Zeinstra2, Margreet Kloppenburg3, Johannes WJ Bijlsma4 and CHECK steering group5, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 3Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Leiden, Netherlands, 4Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht, Netherlands, 5Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht

    Background/Purpose:  Pain and disability related to osteoarthritis (OA) may generally be considered to be chronic, but it is known that its course can be very…
  • Abstract Number: 1110 • 2012 ACR/ARHP Annual Meeting

    Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial

    Emmanuel Maheu1, Christian Cadet2 and Francis Berenbaum1, 1Rheumatology, AP-HP, St Antoine Hospital, Paris, France, 2Rheumatology, Paris, France

    Background/Purpose: Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to…
  • Abstract Number: 1032 • 2012 ACR/ARHP Annual Meeting

    Medial Meniscal Root Tears and the Association with Meniscal Extrusion, Prevalent Cartilage Damage and Longitudinal Cartilage Loss: The MOST Study

    Mohamed Jarraya1, David T. Felson2, Daichi Hayashi1, Frank Roemer3, Yuqing Zhang4, Jingbo Niu5, Michel Crema6, Martin Englund7, John A. Lynch8, Michael C. Nevitt9, James Torner10, C.E. Lewis11 and Ali Guermazi6, 1Department of Radiology, Boston University, Boston, MA, 2Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, 3Radiology, Klinikum Augsburg, Augsburg, Germany, 4Clinical Epidemiology Unit, Boston University, Boston, MA, 5Boston University, Boston, MA, 6Radiology, Boston University, Boston, MA, 7Department of Orthopedics, Lund University, Lund, Sweden, 8Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, 9Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, 10Epidemiology, University of Iowa, Iowa City, IA, 11University of Alabama at Birmingham, Birmingham City, AL

    Background/Purpose: The meniscal root is a ligamentous structure that anchors the posterior horn of the meniscus to the tibial plateau. The association of isolated meniscal…
  • Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting

    Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout

    Eswar Krishnan, Medicine, Standford University, Palo Alto, CA

    Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
  • Abstract Number: 653 • 2012 ACR/ARHP Annual Meeting

    Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare

    Mikhail Olferiev1, Kyriakos A. Kirou1, Elena Gkrouzman1, Dorthe Lundsgaard2, Klaus S. Frederiksen3, Jan Fleckner4 and Mary K. Crow5, 1Hospital for Special Surgery, New York, NY, 2Inflammation Science, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv, Denmark, 3Novo Nordisk A/S, Søborg, Denmark, 4NovoNordisk, Copenhagen, Denmark, 5Department of Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Lupus, a chronic autoimmune disease, is characterized by a variable clinical course, with periods of active disease termed flares. The severity of flares can…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology